Making evidence synthesis accessible to everyone.

CPTO & Co-Founder

Fifteen years building production AI — from clinical-grade genomics in the diagnostic clinic to ML platforms at advertising-platform scale. At Illumina, co-authored Canvas — the copy-number variant caller used in clinical genome sequencing for rare disease and cancer; peer-reviewed work in Cell, Nature Genetics, and Bioinformatics (1,400+ citations, h-index 11). Subsequently scaled ML platforms across Lifebit (federated genomics on UK Biobank-scale cohorts), Hitachi Vantara, Captify (Lead ML Engineer), and Extreme Reach (Director, ML & Data Engineering) — high-throughput, low-latency production AI systems. PhD, Computational Biology, University of Cambridge; MSc Informatics, University of Edinburgh.

Co-Founder

A career bridging cancer research, big-pharma medical affairs, and Cambridge biotech founding. Co-founder and former VP Business Development at Healx — the Cambridge AI rare-disease drug-discovery company ($47M+ raised, Sanofi partnership) — and of three further Cambridge biomed ventures. Senior medical-affairs and clinical-development leadership across Daiichi Sankyo, Kyowa Kirin (Global Product Head, Burosumab, then Cluster Franchise Medical Director, Oncology & Haematology), and AbbVie — spanning oncology, haematology, rare disease, and immunology — with current board service as Non-Executive Director, Innovation Forum. PhD, Cancer Stem Cell Research, University of Cambridge.